Phommasone, Koukeo
van Leth, Frank
Imwong, Mallika
Henriques, Gisela
Pongvongsa, Tiengkham
Adhikari, Bipin
Peto, Thomas J.
Promnarate, Cholrawee
Dhorda, Mehul
Sirithiranont, Pasathorn
Mukaka, Mavuto
Peerawaranun, Pimnara
Day, Nicholas P. J.
Cobelens, Frank
Dondorp, Arjen M.
Newton, Paul N.
White, Nicholas J.
von Seidlein, Lorenz http://orcid.org/0000-0002-0282-6469
Mayxay, Mayfong
Clinical trials referenced in this document:
Documents that mention this clinical trial
The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR
https://doi.org/10.1186/s12936-019-3091-5
The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos
https://doi.org/10.1186/s12936-019-3087-1
Funding for this research was provided by:
Wellcome Trust (101148/Z/13/Z)
Bill and Melinda Gates Foundation (OPP10811420)
Article History
Received: 22 August 2019
Accepted: 25 December 2019
First Online: 3 January 2020
Change Date: 21 January 2020
Change Type: Correction
Change Details: Following publication of the original article [1], it was brought to the authors’ attention that one of the names in the author list had been provided with the incorrect spelling.
Ethics approval and consent to participate
: Participants provided written informed consent by signature or thumbprint for participants older than 15 years. Children aged between 12 and 15 years co-signed or thumb-printed with their parents or guardians. This study received ethical approval by the National Ethics Committee for Health Research (074NIOPH/NECHR, 11th January 2016), Ministry of Health, Lao PDR and Oxford Tropical Research Ethics Committee (OxTREC Reference 19-16, 18th May, 2016), University of Oxford.
: Not applicable as no personal data are included.
: The authors declare that they have no competing interests.